Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Impact of Appointment Reminder Strategies on Smoking Cessation Clinic Attendance (NO-SHOW-NCC)

20. august 2026 oppdatert av: Łukasz Balwicki, Medical University of Gdansk

Effect of Reminder Strategies on No-Show Rates in a Nicotine Cessation Clinic: A Randomized Controlled Trial

The goal of this clinical trial is to learn whether different appointment reminder methods can improve attendance at an anti-smoking (smoking cessation) clinic among adult smokers.

The main question it aims to answer is:

"Which reminder method helps participants come to their scheduled smoking cessation clinic appointments most often?" Researchers will compare different appointment reminder methods with standard appointment scheduling to see if they help participants attend their clinic visits more often.

Participants will:

  • Receive appointment reminders using different methods
  • Come to their scheduled visits at a smoking cessation (anti-nicotine) clinic

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

300

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Pomeranian Voivodeship
      • Gdansk, Pomeranian Voivodeship, Polen, 80-952
        • University Clinical Centre
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jagoda K Arendt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Age ≥ 18 years. Confirmed diagnosis of nicotine dependence (F17 according to the International Classification of Diseases, 10th Revision [ICD-10]) and active patient status at the Smoking Cessation Clinic.
  • Provision of voluntary, written, informed consent to participate in the study and to be contacted by telephone or short text message.
  • Ability to independently provide information and operate a mobile phone.
  • At the time of study enrollment, attendance at an initial visit at the clinic.

Exclusion Criteria

  • Age < 18 years.
  • Lack of written, informed consent to participate in the study.
  • Inability to independently understand the study procedures or provide responses (e.g., due to dementia or a language barrier).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Ingen inngripen: Standard of care - Text message
Participants will receive a standard, automated text message reminding them of their scheduled appointment. The message will be sent 1 day before the scheduled appointment. The content of the message will be limited to logistical information (date, time, and location) and instructions on how to reschedule or cancel the appointment.
Eksperimentell: Text message and standard phone call
Participants will receive a text message (similar to Arm 1) one day before the appointment and, additionally, a phone call from a trained staff member 1-5 days before the appointment. The conversation will follow a strictly standardized script limited solely to confirming the appointment date, without any motivational or therapeutic elements.
Participants will receive a phone call from a trained staff member 1-5 days before the appointment. The conversation will follow a strictly standardized script limited solely to confirming the appointment date, without any motivational or therapeutic elements.
Eksperimentell: Text message and phone call with MINDSPACE elements

Participants will receive a short text message (similar to Arm 1) and a phone call 1-5 days before their appointment. The conversation will follow a standardized script incorporating behavioral intervention (nudging) elements based on the MINDSPACE (Messenger, Incentives, Norms, Defaults, Salience, Priming, Affect, Commitments, Ego) framework. Key components of the script include:

  • Messenger (Sender): Emphasizing that the information comes from the medical team.
  • Norms (Social Norms): Referring to success statistics for regular visits.
  • Commitment: Encouraging verbal confirmation of attendance.
  • Affect (Emotions): Providing short messages reinforcing a sense of support.

Participants will receive a phone call 1-5 days before their appointment. The conversation will follow a standardized script incorporating behavioral intervention (nudging) elements based on the MINDSPACE framework. Key components of the script include:

  • Messenger (Sender): Emphasizing that the information comes from the medical team.
  • Norms (Social Norms): Referring to success statistics for regular visits.
  • Commitment: Encouraging verbal confirmation of attendance.
  • Affect (Emotions): Providing short messages reinforcing a sense of support.
Andre navn:
  • MINDSPACE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Patient attendance at scheduled follow-up visit
Tidsramme: At the second scheduled visit at the Nicotine Cessation Clinic (2-8 weeks after baseline).
Primary Outcome: The primary outcome measure is a binary assessment of patient attendance (Present/Absent) at the scheduled second visit, which takes place 2-8 weeks after the initial visit, as determined by the physician's individual assessment. Attendance will be verified on the day of the scheduled visit based on objective data recorded in the "CliniNET" hospital system.
At the second scheduled visit at the Nicotine Cessation Clinic (2-8 weeks after baseline).

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Impact of sociodemographic and clinical factors on patient attendance
Tidsramme: at baseline and 2 to 8 weeks after enrollment
Secondary Outcomes: Secondary analyses will include an assessment of the impact of sociodemographic and clinical factors based on tests routinely performed as part of a medical visit (age, sex, level of dependence according to the Fagerström Test for Nicotine Dependence (FTND)).
at baseline and 2 to 8 weeks after enrollment

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. august 2026

Primær fullføring (Antatt)

1. april 2027

Studiet fullført (Antatt)

1. april 2027

Datoer for studieregistrering

Først innsendt

7. august 2026

Først innsendt som oppfylte QC-kriteriene

20. august 2026

Først lagt ut (Faktiske)

21. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

21. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

20. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared with other researchers. Due to privacy and confidentiality concerns, as well as applicable data protection laws, including the General Data Protection Regulation (GDPR), de-identified IPD from individual participants will not be made available.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere